ClinicalTrials.gg
CompletedNCT00631475BUILD OLUpdated Feb 4, 2025Results posted

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

A Phase 3 interventional study of Bosentan in Idiopathic Pulmonary Fibrosis, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic pulmonary fibrosis (IPF).

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Actelion
  • Idiopathic Pulmonary Fibrosis
  • bosentan
  • Tracleer
  • Interstitial Lung Disease
  • BUILD 3 (NCT00391443)
03

In context

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

This study's enrollment of 128 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients should have completed all the assessments from the BUILD 3 (NCT00391443) end of study (EOS) visit.

  • Signed prior to initiation of any study-related procedures.
  • Women of must have a negative serum pregnancy test and use reliable methods of during study treatment and for 3 months after study treatment termination.

Exclusion criteria

Exclusion Criteria:

  • Any major violation of protocol AC-052-321 / BUILD 3 (NCT00391443).
  • Pregnancy or breast-feeding.
  • and/or ALT > 3 times the .
  • Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
  • Known to bosentan or any of the .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    1

    For patients who were administered bosentan during BUILD 3 (NCT00391443): Same dose will continue For patients who were administered placebo during BUILD 3 (NCT00391443): Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg

    Drug: Bosentan

Interventions

  • For patients who were administered Bosentan during BUILD 3 (NCT00391443): continue on same dose For patients who were administered placebo during BUILD 3 (NCT00391443): Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)

    Also known as: Tracleer

06

What researchers measure

Primary outcomes

  1. Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

    Mean extent of exposure to bosentan treatment in months

    Time frame: Start of study to end of study, up to 21 months

Secondary outcomes

  1. Number of Patients Exposed to Bosentan Over Time

    Numbers of participants exposed to bosentan treatment over time

    Time frame: Start to end of study, up to 21 months

  2. Adverse Events (AE) Leading to Discontinuation of Study Drug.

    Number of participants with at least one AE that led to permanent discontinuation of study treatment.

    Time frame: Start to end of study, up to 21 months

  3. Treatment-emergent Serious Adverse Events (SAE)

    Number of participants with at least one SAE during the study.

    Time frame: up to 21 months plus 28 days after the end of study drug

  4. Occurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality.

    Number of participants with an increase in ALT and/or AST to \> 3 times upper limit of normal during the study.

    Time frame: up to 21 months, plus 24 hours after the end of study treatment

07

Results

Posted Aug 3, 2012

Participant flow

Patients were enrolled at 61 centers in 15 countries (Australia, Belgium, Canada, Czech Republic, France, Germany, Ireland, Israel, Italy, Japan, South Korea, , Spain, Switzerland, UK, and USA. The first patient started on 5 March 2008 and the last patient, last visit was on 01 April 2010.

Participant flow — Overall Study
MilestoneBosentan Treatment
Started128
Completed83
Not completed45
Withdrew: Death18
Withdrew: Adverse event14
Withdrew: Withdrew consent5
Withdrew: Preparation for lung transplant8

Outcome measures

PrimaryExtent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Mean extent of exposure to bosentan treatment in months

Time frame:
Start of study to end of study, up to 21 months
Reported as:
Mean · months
Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
monthsBosentan Treatment
Extent of Exposure to Bosentan in Patients With Idiopathic Pulmonary Fibrosis (IPF)6.4 ± 4.6
SecondaryNumber of Patients Exposed to Bosentan Over Time

Numbers of participants exposed to bosentan treatment over time

Time frame:
Start to end of study, up to 21 months
Reported as:
Number · Participants
Number of Patients Exposed to Bosentan Over Time
ParticipantsBosentan Treatment
For at least 4 months74
For at least 8 months44
For at least 12 months17
For at least 16 months7
For at least 20 months2
SecondaryAdverse Events (AE) Leading to Discontinuation of Study Drug.

Number of participants with at least one AE that led to permanent discontinuation of study treatment.

Time frame:
Start to end of study, up to 21 months
Reported as:
Number · participants
Adverse Events (AE) Leading to Discontinuation of Study Drug.
participantsBosentan Treatment
Adverse Events (AE) Leading to Discontinuation of Study Drug.32
SecondaryTreatment-emergent Serious Adverse Events (SAE)

Number of participants with at least one SAE during the study.

Time frame:
up to 21 months plus 28 days after the end of study drug
Reported as:
Number · participants
Treatment-emergent Serious Adverse Events (SAE)
participantsBosentan Treatment
Treatment-emergent Serious Adverse Events (SAE)51
SecondaryOccurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality.

Number of participants with an increase in ALT and/or AST to \> 3 times upper limit of normal during the study.

Time frame:
up to 21 months, plus 24 hours after the end of study treatment
Reported as:
Number · participants
Occurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality.
participantsBosentan Treatment
Occurrence of Liver Function Test (LFT: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)) Abnormality.3

Adverse events

Collected over Up to 28 days after the end of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan Treatment—51/128 (39.8%)5/128 (3.9%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventBosentan Treatment
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders23/128
Respiratory failureRespiratory, thoracic and mediastinal disorders4/128
Lower respiratory tract infectionInfections and infestations4/128
PneumoniaInfections and infestations4/128
DyspnoeaRespiratory, thoracic and mediastinal disorders3/128
Lung transplantSurgical and medical procedures3/128
Coronary artery diseaseCardiac disorders2/128
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/128
Pleuritic painRespiratory, thoracic and mediastinal disorders1/128
PneumothoraxRespiratory, thoracic and mediastinal disorders1/128
Most frequent other events
Most frequent other events
EventBosentan Treatment
LIVER FUNCTION TEST ABNORMALInvestigations2/128
DYSPNOEARespiratory, thoracic and mediastinal disorders1/128
IDIOPATHIC PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders1/128
OEDEMA PERIPHERALGeneral disorders1/128

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bosentan Treatment
Mean65.4 ± 8.2
Age, Customized
Age, Customized(participants)Bosentan Treatment
18-40 years1
41-60 years33
61-70 years62
>70 years32
Sex: Female, Male
Sex: Female, Male(Participants)Bosentan Treatment
Female31
Male97
Region of Enrollment
Region of Enrollment(participants)Bosentan Treatment
Australia12
Belgium1
Canada14
Czech Republic1
France3
Germany11
Ireland1
Israel4
Italy2
Japan8
Korea, Republic of5
Spain8
Switzerland4
United Kingdom3
United States51
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2008
First posted
Mar 7, 2008
Start
Apr 2008
Primary completionActual
Apr 2010
CompletionActual
May 2010
Results first posted
Aug 3, 2012
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00631475
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Mar 7, 2008
Start date
Apr 2008
Primary completion
Apr 2010
Completion
May 2010
Results posted
Aug 3, 2012
Last update
Feb 4, 2025

Study contacts

Isabelle Leconte
study chair · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion